The Promise of Pathbreaking Advances in Ovarian Cancer with Nanomedicine

In this episode of Connect Ovar Coffee, Dr. Daniel Heller, Head of Cancer Nanomedicine Lab at Memorial Sloan Kettering Cancer Center joins us to
Talk About The Promise of Pathbreaking Advances in Ovarian Cancer With Nanomedicine. Let's #ConnectOvarCoffee!

[@keyuranil]

Excellent 👍🏿

[@Ovarcome]

Thank you! 🙏

[@leslieandrus7150]

While mucinous ovarian cancer is more rare, there does seem to be a large population amongst us that is caught in either this pre-cancerous or Stage 1. Is there a particular Center that is focused on this subtype? Essentially, how do we get our samples to the right researchers, as survivors?